Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies

References

• Silacci M, Brack S, Schirru G et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics5(9), 2340–2350 (2005).
   PubMed Web of Science ®Google Scholar
• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol.23(9), 1147–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Collins J, Horn N, Wadenback J, Szardenings M. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol.74(4), 317–338 (2001).
   PubMedGoogle Scholar
• Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu. Rev. Med.56, 555–583 (2005).
   PubMed Web of Science ®Google Scholar
• Melkko S, Scheuermann J, Dumelin CE, Neri D. Encoded self-assembling chemical libraries. Nat. Biotechnol.22(5), 568–574 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol.1(1), 37–50 (2005).
   PubMedGoogle Scholar
• Haber DA, Settleman J. Cancer: drivers and passengers. Nature446(7132), 145–146 (2007).
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell10(6), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Hondermarck H. Breast cancer: when proteomics challenges biological complexity. Mol. Cell. Proteomics2(5), 281–291 (2003).
   PubMed Web of Science ®Google Scholar
• Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis21(11), 2235–2242 (2000).
   PubMed Web of Science ®Google Scholar
• Celis A, Rasmussen HH, Celis P et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis20(2), 355–361 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta PB, Kuperwasser C. Disease models of breast cancer. Drug Discov. Today1(1), 9–16 (2004).
   Google Scholar
• Jessani N, Humphrey M, McDonald WH et al. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc. Natl Acad. Sci. USA101(38), 13756–13761 (2004).
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell7(6), 513–520 (2005).
   PubMed Web of Science ®Google Scholar
• Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer7(2), 139–147 (2007).
   PubMed Web of Science ®Google Scholar
• Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible? Electrophoresis21(6), 1054–1070 (2000).
   PubMed Web of Science ®Google Scholar
• Jain M, Venkatraman G, Batra SK. Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging34(7), 973–977 (2007).
   Google Scholar
• Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1. Eur. J. Nucl. Med. Mol. Imaging34(3), 368–377 (2007).
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8), 971–983 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Adkins JN, Qian WJ et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res.4(4), 1073–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics5(18), 4713–4718 (2005).
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res.62(6), 1868–1875 (2002).
   PubMed Web of Science ®Google Scholar
• Celis JE, Gromov P, Cabezon T et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics3(4), 327–344 (2004).
   PubMed Web of Science ®Google Scholar
• Ruhlen RL, Sauter ER. Proteomics of nipple aspirate fluid, breast cyst fluid, milk, and colostrum. Proteomics1(8), 845–852 (2007).
   Google Scholar
• Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science274(5289), 998–1001 (1996).
   PubMed Web of Science ®Google Scholar
• Baker H, Patel V, Molinolo AA et al. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol.41(2), 183–199 (2005).
   PubMed Web of Science ®Google Scholar
• Li C, Hong Y, Tan YX et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics3(4), 399–409 (2004).
   PubMed Web of Science ®Google Scholar
• Nettikadan S, Radke K, Johnson J et al. Detection and quantification of protein biomarkers from fewer than 10 cells. Mol. Cell. Proteomics5(5), 895–901 (2006).
   PubMed Web of Science ®Google Scholar
• Tammen H, Kreipe H, Hess R et al. Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res. Treat.79(1), 83–93 (2003).
   PubMed Web of Science ®Google Scholar
• Pucci-Minafra I, Cancemi P, Marabeti MR et al. Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. Proteomics1(1), 118–129 (2007).
   Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17(10), 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Saghatelian A, Cravatt BF. Assignment of protein function in the postgenomic era. Nat. Chem. Biol.1(3), 130–142 (2005).
   PubMed Web of Science ®Google Scholar
• Roesli C, Neri D, Rybak J-N. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat. Protocols1(1), 192–199 (2006).
   PubMed Web of Science ®Google Scholar
• Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods2(4), 291–298 (2005).
   PubMed Web of Science ®Google Scholar
• Castronovo V, Waltregny D, Kischel P et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol. Cell. Proteomics5(11), 2083–2091 (2006).
   PubMed Web of Science ®Google Scholar
• Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol.5(5), 543–549 (2005).
   PubMed Web of Science ®Google Scholar
• Zardi L, Neri D. Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv. Drug Deliv. Rev.31(1–2), 43–52 (1998).
   Google Scholar
• Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer118(6), 1331–1339 (2006).
   PubMed Web of Science ®Google Scholar
• Silacci M, Brack SS, Spath N et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng. Des. Sel.19(10), 471–478 (2006).
   PubMed Web of Science ®Google Scholar
• Castronovo V, Kischel P, Guillonneau F et al. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics7(8), 1188–1196 (2007).
   PubMed Web of Science ®Google Scholar
• Holmberg A, Blomstergren A, Nord O, Lukacs M, Lundeberg J, Uhlen M. The biotin–streptavidin interaction can be reversibly broken using water at elevated temperatures. Electrophoresis26(3), 501–510 (2005).
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Sgroi DC, Krutzsch H et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res.62(22), 6740–6749 (2002).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol. Cell. Proteomics5(10), 1772–1786 (2006).
   PubMed Web of Science ®Google Scholar
• Liu H, Lin D, Yates JR III. Multidimensional separations for protein/peptide analysis in the post-genomic era. Biotechniques32(4), 898–900, 902 passim (2002).
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• Olsen JV, de Godoy LM, Li G et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics4(12), 2010–2021 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt A, Aebersold R. High-accuracy proteome maps of human body fluids. Genome Biol.7(11), 242 (2006).
   PubMedGoogle Scholar
• de Souza GA, Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol.7(8), R72 (2006).
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins including a large proportion of membranes proteins. Genome Biol.7(9), R80 (2006).
   PubMed Web of Science ®Google Scholar
• Pilch B, Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol.7(5), R40 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol.25(8), 887–893 (2007).
   PubMed Web of Science ®Google Scholar
• van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv. Cancer Res.96, 23–50 (2007).
   PubMed Web of Science ®Google Scholar
• Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation. Proteome Sci.5, 9 (2007).
   Google Scholar
• Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics6(1), 4–8 (2006).
   PubMed Web of Science ®Google Scholar
• Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol. Cell. Proteomics3(6), 531–533 (2004).
   PubMed Web of Science ®Google Scholar
• Durr E, Yu J, Krasinska KM et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat. Biotechnol.22(8), 985–992 (2004).
   PubMed Web of Science ®Google Scholar
• Elias JE, Haas W, Faherty BK, Gygi SP. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat. Methods2(9), 667–675 (2005).
   PubMed Web of Science ®Google Scholar
• Annesley TM. Ion suppression in mass spectrometry. Clin. Chem.49(7), 1041–1044 (2003).
   PubMed Web of Science ®Google Scholar
• Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol.7(12), 952–958 (2006).
   PubMed Web of Science ®Google Scholar
• Miyagi M, Rao KC. Proteolytic 18O-labeling strategies for quantitative proteomics. Mass Spectrom. Rev.26(1), 121–136 (2007).
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics3(12), 1154–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics5(1), 4–15 (2005).
   PubMed Web of Science ®Google Scholar
• Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl Acad. Sci. USA100(12), 6940–6945 (2003).
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem.389(4), 1017–1031 (2007).
   PubMed Web of Science ®Google Scholar
• Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J. Immunol. Methods103(1), 121–129 (1987).
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallionimeni A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med.4(7), 844–847 (1998).
   PubMed Web of Science ®Google Scholar
• Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics5(4), 573–588 (2006).
   PubMed Web of Science ®Google Scholar
• Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science301(5641), 1884–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Service RF. American Chemical Society meeting. Tiny transistors scout for cancer. Science300(5617), 242–243 (2003).
   Google Scholar
• Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol.25(23), 3525–3533 (2007).
   PubMed Web of Science ®Google Scholar
• Boyd CD, Pierce RA, Schwarzbauer JE, Doege K, Sandell LJ. Alternate exon usage is a commonly used mechanism for increasing coding diversity within genes coding for extracellular matrix proteins. Matrix13(6), 457–469 (1993).
   PubMedGoogle Scholar
• Zardi L, Carnemolla B, Siri A et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J.6(8), 2337–2342 (1987).
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Neri D, Castellani P et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer68(3), 397–405 (1996).
   PubMed Web of Science ®Google Scholar
• Neri D, Carnemolla B, Nissim A et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol.15(12), 1271–1275 (1997).
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Bestagno M et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer102(1), 75–85 (2002).
   PubMed Web of Science ®Google Scholar
• Santimaria M, Moscatelli G, Viale GL et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res.9(2), 571–579 (2003).
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat. Rev. Cancer5(6), 436–446 (2005).
   PubMed Web of Science ®Google Scholar
• Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov.5(2), 147–159 (2006).
   PubMed Web of Science ®Google Scholar